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Abstract
Background. The causes of accelerated atherosclerosis in
end-stage renal disease (ESRD) patients are unknown, al-
though recent studies have suggested that Chlamydia pneu-
moniae (Cp) infection and inflammation might be con-
tributing factors. We aimed to evaluate the association
of carotid atherosclerosis progression with Cp infection
and inflammation in patients undergoing peritoneal dialy-
sis (PD).
Methods. This is a prospective observational study. A total
of 52 non-diabetic prevalent PD patients were included.
The intima-media thickness of a common carotid artery
(CCA-IMT) was measured at baseline and after 36 months
by B-mode ultrasonography. Serum antibodies to Cp and
inflammatory markers were obtained at the time of initial
measurement of the CCA-IMT.
Results. CCA-IMT progressors (CCA-IMT ≥ 0.015
mm/year) had a higher prevalence of seropositivity for Cp
IgA antibody, a higher level of Cp IgA antibodies indices,
log IL-(interleukin-)6, and intercellular adhesion molecule-
1 (ICAM-1) compared to the non-progressors (CCA-
IMT< 0.015 mm/year). On multivariate analysis, Cp IgA
index and log IL-6were independent risk a factors for CCA-
IMT progression. Also, Cp IgA index had independent pos-
itive correlation with the magnitude of annualCCA-IMT.
Cp IgA antibody seropositive patients showed significantly
highermean annualCCA-IMT than seronegative patients.
Moreover, patients with both positive Cp IgA antibodies
and elevated IL-6 above the median level showed higher
CCA-IMT than those with either factor alone.
Conclusions. Our data showed that Cp and inflammation
were significant risk factors of CCA-IMT change in PD
patients. This study strengthens evidence that Cp is involved
in the pathogenesis of atherosclerosis and also suggests that
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the effect of Cp infection under high inflammatory status
might be a risk factor for progression of atherosclerosis.
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Introduction
Although continuous advances in dialysis and renal trans-
plantation have significantly decreased the mortality rate
from end-stage renal disease (ESRD) patients undergoing
dialysis still have a higher mortality rate than the general
population, and cardiovascular disease is the main con-
tributor to this higher mortality. This phenomenon cannot
be simply explained by the traditional cardiovascular risk
factors such as hypertension, diabetes mellitus, cigarette
smoking and dyslipidaemia. Therefore, much attention has
recently been paid to on the non-traditional risk factors,
such as chronic inflammation and infection.
Chlamydia pneumoniae (Cp) has been the most impli-
cated micro-organism associated with atherosclerosis. It
has been proposed that the organism infects the vessel
wall, induces inflammatory mediators and promotes vas-
cular smooth muscle proliferation [1]. A previous study
has reported an increased prevalence of Cp seropositivity
in ESRD patients compared with the general population
[2]. Several reports have described a relationship between
Cp and atherosclerosis in patients on haemodialysis [2–4].
While it is still under debate, Cp infection may be a risk
factor for cardiovascular mortality in patients on continu-
ous ambulatory peritoneal dialysis (CAPD) [5,6]. However,
there has been no prospective study to evaluate the effect of
Cp on the progression of atherosclerosis or morphological
change of artery in CAPD patients.
Inflammatory processes play an important role in
the pathogenesis of atherosclerosis, and elevated serum
markers of vascular wall inflammation, such as IL-
(interleukin-)6, intercellular adhesion molecule-1 (ICAM-
1), vascular adhesion molecule-1 (VCAM-1), C-reactive
C© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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protein (CRP) and high sensitivity CRP (hsCRP) have been
shown to predict cardiovascular events.
The measurement of the intima-media thickness of com-
mon carotid artery (CCA-IMT) assessed by high-resolution
duplex ultrasonography has been used as a marker for sub-
clinical atherosclerosis and predicting future cardiovascular
disease [7].
We undertook this prospective study to investigate a pos-
sible association of Cp infection and markers of inflamma-
tion with changes in CCA-IMT.
Subjects and methods
Study population
We initially performed baseline carotid duplex ultrasonog-
raphy and biochemical analyses in 64 non-diabetic CAPD
patients at a single dialysis unit of Severance hospital.
We followed the patients for 36 months thereafter. Dur-
ing this period, 12 patients were excluded from the study,
5 were expired, 3 received kidney transplantation and 3
were switched to haemodialysis. Therefore, 52 (26 male,
mean age 51.8± 10.8 years, range 32–74) out of 64 pa-
tients undertook follow-up carotid duplex ultrasonography
after 36.0± 0.3months of baseline ultrasonography. Causes
of ESRD were chronic glomerulonephritis in 17 patients
(32.7%), hypertension in 12 (23.1%), polycystic kidney
disease in 2 (3.8%), and other (or unknown) causes in
21 (40.4%). Patients with diabetes mellitus, malignancy,
autoimmune disease, general infection sign (fever, leuko-
cytosis) and CAPD related infection (exit site infection,
peritonitis) in the recent 6 months were excluded to avoid
the potential confounding effects of these comorbid condi-
tions. In addition, patients who had a history of coronary
artery disease, cerebrovascular disease and/or peripheral
vascular disease, and CAPD duration less than 6 months
were not included. All patients received PD using a glucose-
based lactate buffered solution. Informed consents were
obtained from all study subjects.
Carotid ultrasonography
In all patients, both carotid arteries were examined with a
duplex scanner (Toshiba, Tokyo, Japan) using a 7.5 MHz
linear array transducer. All scans, both baseline and follow-
up, were performed by the same trained sonographer.
Each subject was examined in the supine position in a
semi-dark room. The far wall of the CCA-IMT, 0.5–1.0 cm
proximal to the beginning of the carotid bulb, was used
for measurements of CCA-IMT and lumen diameter. The
CCA-IMT was defined as the distance between the leading
edge of the lumen-intima echo and the leading edge of the
media-adventitia echo. The lumen diameter was defined as
the distance between the leading edge of the intima-lumen
echo of the near wall and that of the lumen-intima echo of
the far wall. The mean values of the CCA-IMT and lumen
diameter were calculated from at least two measurements
for each artery. A carotid plaque was defined as a localized
intima-media thickening of greater than 1 mm with a min-
imum 100% increase in thickness compared with adjacent
wall segments. The cross-sectional intima-media area (cIM
area) of the artery was calculated using the following for-
mula: 3.14 × [(lumen diameter/2 + CCA-IMT)2 − (lumen
diameter/2)2] [8].
Wemeasured the mean CCA-IMT at the onset and end of
the study and evaluated the difference in the CCA-IMT over
36months. For the assessment of factors that affect changes
in CCA-IMT, the patients were divided into two groups, the
progressors and non-progressors, based on the mean annual
increment of CCA-IMT (CCA-IMT, mm/year). Progres-
sors were defined as those with a mean annualCCA-IMT
≥ 0.015 mm/year, whereas non-progressors as those with
a CCA-IMT< 0.015 mm/year according to the result of
the meta-analysis which estimated the mean annual change
in CCA-IMT among control groups from 13 published ran-
domized placebo-controlled studies [7].
Biochemical analyses
A blood sample was drawn after a 12-h fast on the
same day of the baseline carotid ultrasonography exam-
ination. Haemoglobin (g/dL), haematocrit (%), creatinine
(mg/dL), albumin (g/dL), total cholesterol (mg/dL), triglyc-
eride (mg/dL), high-density lipoprotein (HDL)-cholesterol
(mg/dL), calcium (mg/dL) and phosphate (mg/dL) were
measured. The enzymatic method was used to measure
total cholesterol and triglyceride. The results were ana-
lyzed using a Hitachi 736–40 automated analyzer. HDL-
cholesterol was measured by selective inhibition and the
direct enzymatic method (Daichii, Tokyo, Japan) and low-
density lipoprotein (LDL)-cholesterol was estimated by
the Friedewald formula: LDL-cholesterol (mg/dL)= total
cholesterol (mg/dL)−HDL-cholesterol (mg/dL)− triglyc-
eride (mg/dL) / 5. CRP, hsCRP and IL-6 were measured
as indicators of chronic inflammation. hsCRP was mea-
sured by a BNII nephelometer analyzer (Dade Behring
Inc., Newark, DE, USA). Serum IL-6 (Pierce endogen,
Rockford, Italy), ICAM-1 and VCAM-1 (R&D system Eu-
rope Ltd, Abingdon, UK) levels were measured by enzyme-
linked immunosorbent assay (ELISA).
IgA and IgG antibodies to Cp were measured by ELISA
(Bioclone, Sydney, Australia). The index value for distin-
guishing between positive and negative samples was calcu-
lated from the formula
Cut-off value (COV) = (mean negative control OD X K)
+ 0.20
Index value = (mean sample OD X K)/COV
where ‘mean negative control OD’ is the mean value of
negative control serum absorbance at 405 nm in duplicate
and K is the ratio of the positive serum sample value to
the mean values of positive control serum absorbance at
405 nm.
Seropositivity of IgG and IgA to Cpwas defined as an in-
dex value > 1.10. The sensitivity and specificity of Cp IgG
and IgA by ELISA compared to microimmunofluorescence
(MIF) assay were as follows: The sensitivity was 90.4% for
detecting IgG and 84.6% for IgA, and the specificity was
89.9% for detecting IgG and 86.7% for IgA [9].
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Statistical analysis
All the statistics were performed with SPSS (Windows
release 12.0) for personal computers. P-values less than
0.05 were considered statistically significant. Data were
expressed as mean± standard deviation. Differences be-
tween the two groups were analyzed by the Student’s t-test
and the Chi-square test and among three or more groups
by ANOVA. A multiple regression analysis was used to ex-
amine the relationship between atherosclerotic change and
select variables.
Results
Demographic characteristics and biochemical data
Clinical and biochemical data from the study populations
are shown in Table 1.
Changes in carotid duplex ultrasonography parameters
A significant increase in the mean values of CCA-
IMT (0.74± 0.11 versus 0.79± 0.12 mm,P< 0.001), and
the cIM area (19.99± 4.57 versus 22.66± 5.12 mm2,
P< 0.001) were noted between baseline and follow-up
Table 1. The initial clinical and biochemical characteristics of patients
Age (years) 51.8± 10.8 (32–74)
Sex (M:F) 26:26
CAPD duration (months) 58.6± 40.8 (7–151)
Body mass index (kg/m2) 23.5± 3.2
Mean arterial pressure
(mmHg)
103.7± 16.0
Hemoglobin (g/dL) 10.3± 1.4
Hematocrit (%) 30.5± 4.3
Creatinine (mg/dL) 11.3± 2.4
Albumin (g/dL) 3.7± 0.4
Calcium (mg/dL) 9.5± 0.8
Phosphorus (mg/dL) 5.1± 1.3
Calcium-Phosphorus product
(mg2/dL2)
48.39± 12.85
Intact parathyroid hormone
(pg/mL)
323.42± 301.34
Total cholesterol (mg/dL) 177.9± 29.2
Triglyceride (mg/dL) 145.7± 106.4
HDL-cholesterol (mg/dL) 50.0± 14.5
LDL-cholesterol (mg/dL) 103.8± 31.4
C-reactive protein (mg/dL) 0.35± 0.44
High sensitivity C-reactive
protein (mg/L)
2.70± 4.93 (0.17–31.70)
Interleukin-6 (pg/mL) 27.46± 87.37 (0.3–428.5)
Log interleukin-6 0.65± 0.66 (−0.52–2.63)
Cp IgA antibody index 1.21± 0.57 (0.43–3.71)
Cp IgG antibody index 1.38± 0.89 (0.54–4.84)
Positive IgA to Cp, n (%) 24 (46.2%)
Positive IgG to Cp, n (%) 26 (50.0%)
Intercellular adhesion
molecule-1 (ng/mL)
273.00± 92.99 (89.92–567.54)
Vascular cell adhesion
molecule-1 (ng/mL)
1795.51± 311.78 (1292.12–2519.21)
Data are mean± SD or mean±SD (range). CAPD: continuous ambula-
tory peritoneal dialysis; HDL-cholesterol: high-density lipoprotein choles-
terol; LDL-cholesterol: low-density lipoprotein cholesterol; Cp: Chlamy-
dia pneumoniae.
Table 2. The carotid ultrasonographic parameters of patients over 3 years
(n= 52)
Baseline Follow-up P-value
CCA-IMT (mm) 0.74± 0.11 0.79± 0.12 <0.001
cIM area (mm2) 19.99± 4.57 22.66± 5.12 <0.001
Presence of plaque
Unilateral, n (%) 10 (19.2) 12 (23.1) NS
Bilateral, n (%) 5 (9.6) 6 (11.5) NS
Total, n (%) 15 (28.8) 18 (34.6) NS
Data are mean±SD. NS: not significant; IMT: intima-media thickness of
common carotid artery; cIM area: calculated intima-media area.
measurements. The mean annualCCA-IMT was 0.015±
0.018 mm/year. The percentage of patients with carotid
plaques did not change significantly (Table 2). To analyze
factors that affect changes in CCA-IMT, patients were di-
vided into two groups according to the change in CCA-IMT.
In the progressors (annual CCA-IMT ≥ 0.015 mm/year,
n= 31), the mean CCA-IMT significantly increased from
0.74± 0.12 mm to 0.82± 0.12 mm (P< 0.001) and the
mean cIM area significantly increased from 20.00 ±
4.84 mm2 to 23.68± 5.06 mm2 (P< 0.001). The propor-
tion of patients with carotid plaque increased, but was not
statistically significant (Table 3). The mean annualCCA-
IMT was significantly higher in the progressors than in
the non-progressors (0.028± 0.010 versus−0.005± 0.001,
P< 0.01).
Clinical and biochemical parameters in the CCA-IMT
progressors and non-progressors
There were no significant differences in age, sex, smok-
ing, body mass index, mean arterial pressure, haemoglobin,
haematocrit, albumin, calcium, phosphorus, intact parathy-
roid hormone, total cholesterol and triglyceride level be-
tween the progressors and the non-progressors. However,
the progressors had lower HDL-cholesterol levels than the
non-progressors (41.5± 11.8 versus 50.1± 16.7 mg/dL,
P< 0.05). LDL-cholesterol was higher in the progressors,
but was not statistically significant (P= 0.07). Among in-
dicators of Cp infection and inflammation, CRP, hsCRP,
IgG antibody index to Cp and VCAM-1 were higher in
the progressors but not with statistical significance. How-
ever, log IL-6 (0.90± 0.69 versus 0.32± 0.43, P< 0.001),
IgA antibody index to Cp (1.37± 0.64 versus 0.97± 0.33,
P< 0.01) and ICAM-1 level (294.29± 96.81 versus
241.58± 79.09 ng/mL, P< 0.05) were significantly higher
in the progressors than the non-progressors (Table 4).
Also prevalence of seropositivity of IgA to Cp was sig-
nificantly higher in the progressors (58.1 versus 28.6%,
P< 0.05), whereas seropositivity of IgG to Cp was not
different.
On multiple logistic regression analysis adjusted for age,
sex, log IL-6, Cp IgA antibody index, HDL-cholesterol
and ICAM-1, the Cp IgA index [HR= 1.54 per 0.1 in-
crease (1.07–2.22), P= 0.019] and log IL-6 [HR= 1.24
per 0.1 increase (1.04–1.54), P= 0.046] were independent
risk factors of CCA-IMT progression, while ICAM-1,
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Table 3. Comparison of carotid ultrasonographic parameters between baseline and follow-up study
Non-progressors (n= 21) Progressors (n= 31)
Baseline Follow-up Baseline Follow-up
CCA-IMT (mm) 0.75± 0.10 0.74± 0.10 0.74± 0.12 0.82± 0.12∗
cIM area (mm2) 19.97± 4.26 21.16± 4.38 20.00± 4.84 23.68± 5.06∗
Presence of plaque, n (%) 5 (25.0) 6 (28.6) 10 (31.3) 12 (37.5)
Data are mean±SD. Progressors: annual IMT ≥ 0.015 mm/year; non-progressors: annual IMT< 0.015
mm/year. CCA-IMT: intima-media thickness of common carotid artery; cIM area: calculated intima-media area.
∗P< 0.001 versus baseline.
Table 4. Comparison of clinical and biochemical characteristics between progressors and non-progressors
Non-progressors (n= 21) Progressors (n= 31) P-value
Age (years) 51.3± 10.3 52.1± 11.3 NS
Sex (M:F) 10:11 16:15 NS
Smoking, n (%) 5 (25.0) 9 (28.1) NS
CAPD duration (months) 57.2± 42.6 59.6± 40.2 NS
Body mass index (kg/m2) 22.8± 3.4 24.1± 3.1 NS
Mean arterial pressure (mmHg) 103.3± 13.6 103.9± 17.6 NS
Haemoglobin (g/dL) 10.1± 1.5 10.4± 1.3 NS
Haematocrit (%) 30.5± 5.0 30.4± 3.8 NS
Albumin (g/dL) 3.6± 0.4 3.7± 0.4 NS
Calcium (mg/dL) 9.5± 0.9 9.5± 0.7 NS
Phosphorus (mg/dL) 5.0± 1.4 5.1± 1.2 NS
Calcium–phosphorus product (mg2/dL2) 47.87± 14.65 48.74± 11.71 NS
Intact parathyroid hormone (pg/mL) 345.63± 349.86 308.37± 268.67 NS
Total cholesterol (mg/dL) 173.1± 26.9 181.2± 30.7 NS
Triglyceride (mg/dL) 143.9± 149.7 146.9± 65.5 NS
HDL-cholesterol (mg/dL) 50.1± 16.7 41.5± 11.8 <0.05
LDL-cholesterol (mg/dL) 94.2± 31.5 110.3± 30.1 NS
C-reactive protein (mg/dL) 0.31± 0.50 0.38± 0.41 NS
High sensitive C-reactive protein (mg/L) 2.61± 3.12 2.83± 6.87 NS
Log interleukin-6 (pg/mL) 0.32± 0.43 0.90± 0.69 <0.01
Cp IgA antibody index 0.97± 0.33 1.37± 0.64 <0.01
Cp IgG antibody index 1.25± 0.85 1.46± 0.92 NS
Positive IgA to Cp, n (%) 6 (28.6) 18 (58.1) <0.05
Positive IgG to Cp, n (%) 9 (42.6) 17 (54.8) NS
Intercellular adhesion molecule-1 (ng/mL) 241.58± 79.09 294.29± 96.81 <0.05
Vascular cell adhesion molecule-1 (ng/mL) 1764.88± 320.48 1816.26± 309.32 NS
Data are mean±SD. Progressors: annual IMT ≥ 0.015 mm/year, non-progressors: annual IMT< 0.015 mm/year. NS: not significant; CAPD:
continuous ambulatory peritoneal dialysis; HDL-cholesterol: high-density lipoprotein cholesterol; LDL-cholesterol: low-density lipoprotein cholesterol;
Cp: Chlamydia pneumoniae.
HDL-cholesterol and body mass index were not. When the
Cp IgA antibody index was replaced by Cp IgA seropos-
itivity, Cp IgA seropositivity [HR= 8.32 (1.28–54.14),
P= 0.027] was the only independent risk factor of CCA-
IMT progression (Table 5).
Magnitude of CCA-IMT progression and traditional risk
factors
The mean annual CCA-IMT (m/year) showed a signifi-
cant positive correlation with the initial body mass in-
dex (r= 0.320, P< 0.05) and LDL-cholesterol (r= 0.335,
P< 0.05), and a negative correlation with HDL-cholesterol
(r=−0.392, P< 0.01) (Figure 1). In contrast, there was no
significant association between mean annual CCA-IMT
and age, mean arterial pressure, haemoglobin, albumin, to-
tal cholesterol and triglyceride (data not shown).
Table 5. Predictors of progression of intima-media thickness (multiple
logistic regression analysis)
Variablesa HR 95% CI P-value
Cp IgA antibody index per 0.1 1.54 1.07–2.22 0.019
Log interleukin-6 per 0.1 1.24 1.04–1.54 0.046
HDL-cholesterol (mg/dL) 0.93 0.87–1.00 0.056
Intercellular adhesion molecule-1 (ng/mL) 1.01 1.00–1.02 0.141
Variablesb HR 95% CI P-value
Cp IgA seropositivity 8.32 1.28–54.14 0.027
Log interleukin-6 per 0.1 1.20 0.98–1.49 0.080
HDL-cholesterol (mg/dL) 0.94 0.88–1.01 0.086
Intercellular adhesion molecule-1 (ng/mL) 1.01 1.00–1.02 0.089
aAdjusted for age, sex, log IL-6, Cp IgA antibody index, HDL-cholesterol
and ICAM-1.
bAdjusted for age, sex, log IL-6, Cp IgA seropositivity, HDL-cholesterol
and ICAM-1.
HR: hazard ratio; CI: confidence interval; Cp: Chlamydia pneumoniae;
HDL-cholesterol: high-density lipoprotein cholesterol.
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Fig. 1. Mean annual intima-media thickness of common carotid artery showed positive correlation with initial body mass index, LDL-cholesterol
and negative correlation with HDL-cholesterol. LDL: low density lipoprotein; HDL: high density lipoprotein.
Table 6. Results ofmultiple linear regression analysis for the determinants
of the independent factors associated with progression of intima-media
thickness
Multiple R= 0.647 ß P-value
Cp IgA index 0.326 <0.01
HDL-cholesterol −0.272 <0.05
Cp: Chlamydia pneumoniae; HDL-cholesterol: high-density lipoprotein
cholesterol.
Magnitude of CCA-IMT progression and Cp infection,
inflammatory markers
The annual CCA-IMT was significantly correlated with
the IgA antibody index to Cp (r= 0.392, P< 0.01), ICAM-
1 (r= 0.347, P< 0.05) and log IL-6 (r= 0.400, P< 0.01)
(Figure 2). However, no significant correlations were found
between the mean annual CCA-IMT and CRP, hsCRP,
IgG antibody index to Cp and VCAM-1 (data not shown).
A stepwise multiple linear regression analysis showed that
index of Cp IgA antibody and HDL-cholesterol were in-
dependently associated with the mean annual CCA-IMT
(P< 0.05) after adjustment for age, body mass index, log
IL-6, ICAM-1 and LDL-cholesterol (Table 6).
Changes in carotid duplex ultrasonographic findings and
differences of baseline risk factors between Cp IgA
seropositive and seronegative patients
Cp IgA seropositive patients (n= 24) showed signifi-
cantly higher mean annual CCA-IMT (0.020± 0.019
versus 0.010± 0.016 mm/year, P< 0.05) and log IL-6
levels (0.80± 0.67 versus 0.49± 0.45, P< 0.05) than
seronegative patients (Figure 3). The mean annual cIM
area was higher in seropositive patients, but did not
reach statistical significance. Among traditional and non-
traditional risk factors, only log IL-6 was significantly
higher in IgA seropositive patients (0.80± 0.69 versus
0.49± 0.45, P< 0.05). Moreover, when patients were strat-
ified into four groups according to Cp IgA serology
status and IL-6 levels (high log IL-6 ≥ 0.455: median
value of log IL-6; low log IL-6< 0.455), the magni-
tude of the annual CCA-IMT was highest in the Cp
IgA seropositive and high log IL-6 group (0.030± 0.009
mm/year, n= 14) (versus IgA seronegative and low log IL-6
group, n= 16, 0.008± 0.017 mm/year, P< 0.01; ver-
sus IgA seronegative and high log IL-6 group, n= 12,
0.013± 0.015 mm/year, P< 0.05; versus IgA seropositive
and low log IL-6 group, n= 10, 0.006± 0.020 mm/year,
P< 0.01) (Figure 4).
Fig. 2. Mean annual intima-media thickness showed positive correlation with Chlamydia pneumoniae IgA index, ICAM-1 and log IL-6. ICAM-1:
intercellular adhesion molecule-1; IL-6: interleukin-6.
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Fig. 3. Chlamydia pneumoniae IgA antibody seropositive patients (n= 24) showed significantly higher mean annual intima-media thickness and log
interleukin-6 level compared with seronegative patients. ∗P< 0.05 versus seronegative; Cp: Chlamydia pneumoniae.
Fig. 4. Group of patients with Chlamydia pneumoniae IgA antibody
seropositive and high log IL-6 (≥ 0.455: median of log IL-6) showed
a higher mean annual intima-media thickness of common carotid artery
than other groups of patients. ∗P< 0.01 versus IgA seropositive and high
log IL-6; †P< 0.05 versus IgA seropositive and high log IL-6. IMT: intima-
media thickness; Cp: Chlamydia pneumoniae; IL-6: interleukin-6.
Discussion
Chronic persistent infection in dialysis patients, a non-
traditional cardiovascular risk factor, could have rationale
accounting for the atherogenic property of chronic inflam-
mation. Many reports have suggested that infectious agents
can evoke cellular and molecular changes that might cause
or accelerate the atherosclerotic process. Among these
pathogens, Cp, a Gram-negative obligate intracellular bac-
terium, has the strongest epidemiological evidence for an
associationwith cardiovascular and cerebrovascular disease
[1]. Cp is a common respiratory pathogen responsible for a
wide range of chronic inflammatory conditions. It could be
disseminated inside monocytes and macrophages from the
respiratory tract to susceptible tissues including arteries. In-
deed, local infection of Cp, as determined by the presence of
chlamydial DNA, antigens or elementary bodies was found
in 52% of atheromatous lesions but in only 5% of control
samples [1]. In addition, there are several experimental ev-
idences about initiation or progression of atherosclerosis
by Cp infection. Cp infection in human monocytic cells
induces various cytokines, such as tumor necrosis factor-α,
IL-1 and IL-6 that are associated with the development of
inflammation and atherosclerosis in an in vitro study [10].
Also,Kalayoglu et al. demonstrated thatCp lipopolysaccha-
ride induced the foam-cell formation ofmacrophages that is
one of the important processes of early atherosclerosis [11].
Moreover, Cp secretes a protease-like activity factor for de-
grading host cell transcription factors, which is required for
major histocompatibility complex antigen expression. This
mechanism may help the organism evade host immunity
resulting in chronic persistent infection [12]. In addition
to these in vitro studies, Cp infection was demonstrated to
accelerate the complex atherosclerotic lesions in an in vivo
study with Apo E3-leiden mice [13]. In spite of these quite
strong experimental evidences, there have been controver-
sies over seroepidemiological studies on ESRDpatients and
the general population regarding the atherogenic properties
of Cp and its significance as a risk factor for cardiovas-
cular morbidity and mortality. In ESRD patients, several
prospective trials demonstrated higher cardiovascular mor-
bidity and mortality rates in Cp seropositive patients com-
pared to seronegative patients [5,6]. Moreover, Kato et al.
have reported in a cross-sectional study that IgA antibody
titer to Cp in patients on haemodialysis has a positive corre-
lation with the maximal diameter of carotid artery plaques
[3]. They later suggested IgA seropositivity to Cp as an
independent risk factor for IMT progression in haemodial-
ysis patients in a prospective study over 4 years [4]. The
important or considerable role of Cp in atherosclerosis was
further supported by the prospective study by Nishimura
et al. They showed that Cp IgA seropositivity by the
ELISA method is an independent risk factor for coro-
nary artery stenosis on angiography in haemodialysis pa-
tients [14]. In accordance with these reports, our data
clearly indicated that Cp IgA seropositivity is an inde-
pendent risk factor for CCA-IMT progression, and the
level of IgA antibody index to Cp has a significant
positive correlation with the severity of CCA-IMT pro-
gression after adjustment for traditional risk factors and
the levels of inflammatory markers. Cp IgA antibodies
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have a very short half-life; thus, IgA seropositivity
is considered as a better marker for chronic infection or
recent re-infection. A report of meta-analysis indicated that
IgA seropositivity has a stronger association with coronary
heart disease than IgG seropositivity [15]. On the other
hand, a recent prospective observational study for patients
on haemodialysis showed that Cp seropositivity does not
increase all-cause and cardiovascular mortality [16]. In ad-
dition, in a univariate analysis Zoccali et al. reported that
Cp IgA seropositivity is associated with higher cardiovas-
cular mortality and morbidity in patients on haemodialysis,
but this effect lost its statistical significance after adjust-
ment for conventional risk factors, such as age, smoking,
diabetes and hypercholesterolaemia [17]. These two studies
implied that serologic assessment by the detection of Cp an-
tibody might not have clinical availability for the risk factor
of atherosclerosis in patients maintaining haemodialysis.
However, these results cannot refute the capability of Cp to
induce atherosclerosis as proven by in vitro and in vivo
experimental studies [10–13]. This might be due to the
methodological limitation of the serologic assay alone to
detect vascular Cp infection. Because this organism is dif-
ficult to culture and neither pathologic diagnosis from ar-
terial tissue nor Cp DNA detection by polymerase chain
reaction (PCR) in cultured peripheral blood mononuclear
cells is possible for clinical application, antibody detection
by serologic assay is currently the only clinically avail-
able method and routine approach to identify Cp infection.
However, several reports suggested that this method has
a higher prevalence of positive results than other meth-
ods of Cp identification, such as DNA detection by PCR
and culture in the general population as well as in ESRD
patients. Also, there is a lack of evidence for an associa-
tion between local vascular infection and positive serology
[18]. Although serologic assay of Cp alone could be con-
sidered less valid based on these conflicting reports, Cp
seropositivity limited to high inflammatory status could
obtain clinical significance with the hypothesis that Cp
infection leads to the pathogenesis of atherosclerosis by
causing chronic inflammation. In addition, seroepidemio-
logical studies for ESRD patients found a positive corre-
lation between Cp IgA titer and IL-6 level, which is the
most potent atherogenic pro-inflammatory cytokine and a
growth factor for vascular smooth muscle cell [3]. Higher
IL-6 levels were also observed in IgA seropositive patients
compared with negative patients [19]. Our results showed
that IL-6 is significantly higher in Cp IgA seropositive pa-
tients in accordance with the previous reports. CCA-IMT
progression was highly enhanced in Cp IgA seropositive
patients, especially in high inflammatory status assessed
by IL-6 but not in patients with low inflammatory sta-
tus. These findings suggest that Cp may trigger the pro-
duction of this pro-inflammatory, atherogenic cytokine re-
sulting in the aggravation of atherosclerosis or at least it
can be speculated that this organism accelerates the pro-
cess of atherosclerosis only in the case of high inflam-
matory status. Thus, it is possible that the serologic as-
say of Cp combined with the measurement of inflamma-
tory markers especially IL-6 could be of help in predicting
the progression of atherosclerosis in patients undergoing
CAPD.
The limitations of this study should be considered. First,
we used an ELISA method to detect antibodies of Cp, not a
MIF assay. Although the MIF method is recommended for
serologic assays because of its high sensitivity and speci-
ficity, the interpretation of the results can be time consum-
ing, subjective and have poor reproducibility [20]. On the
other hand, the ELISA method is relatively simple, more
objective, reproducible and clinically applicable due to the
photometrical interpretationmethod used to detect Cp. Sec-
ond, we relied on a single blood sample from each patient
and thus cannot account for a possible variation in IgA
seropositivity and IgA antibody index to Cp over time.
However, we excluded the patients who had symptoms and
signs of acute infection. Therefore, initial IgA antibody
seropositivity and index were not related to acute infection
of Cp, but reflect a chronic persistent infection. Third, only
52 patients were studied and our data need to be confirmed
in a larger group.
In conclusion, the present study showed that Cp IgA
seropositivity in high inflammation status might be an im-
portant clinical risk factor for atherosclerosis in patients
undergoing CAPD, and the Cp serologic test by the ELISA
method in combination with a test for IL-6 level could be a
useful predictor of future atherosclerosis.
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